Immunomodulatory Agents for Multiple Myeloma

Dear Colleagues,

Immunomodulatory agents (IMiDs) have changed the treatment paradigms in multiple myeloma (MM) and truly improved the survival of multiple myeloma patients. The outcomes of thalidomide-based therapy resulted in the introduction of the first effective drug with a biological mechanism of action in MM. The drug was incorporated into all phases of MM and substantially contributed to the redirection from conventional chemotherapy to immune-mediated therapy.

Lenalidomide and pomalidomide, next-generation IMiDs, have become the backbone of MM treatment and most recently used combined regimens that gain their potential from the accumulative interaction of novel drugs with IMiDs (especially proteasome inhibitors and monoclonal antibodies). A new generation of IMiDs is being tested in both preclinical as well as clinical research.

This Special Issue, “Immunomodulatory Agents for Multiple Myeloma”, aims to clarify the mechanism of action of IMiDs, their position within current strategies of MM therapy, as well as their advantages or pitfalls within routine clinical practice.

We welcome original basic, translational, as well as clinical research articles and review articles leading to a comprehensive overview of IMiD-based therapy in MM.

Dr. Jiří Minařík
Dr. Sabina Ševčíková
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.